Royal Marsden Nhs Foundation Trust
Clinical trials sponsored by Royal Marsden Nhs Foundation Trust, explained in plain language.
-
Zapping resistant tumors: could targeted radiation buy more time for prostate cancer patients?
Disease control CompletedThis trial tested whether a precise type of radiation called SBRT could slow the growth of metastatic prostate cancer in men whose disease was starting to worsen despite hormone therapy. 86 men with one or two growing tumors received SBRT while continuing their current hormone dr…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy shows promise in controlling advanced lung cancer
Disease control CompletedThis early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiation is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembrolizum…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy for rare sarcoma shows promise in early trial
Disease control CompletedThis early-phase trial tested whether adding a drug called avelumab to radiation therapy is safe for people with advanced soft-tissue sarcoma that has spread. Twelve adults with at least two tumors not curable by standard treatments took part. The main goal was to check for side …
Phase: PHASE1, PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental combo shows promise for rare sarcomas
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine) is safe for people with two rare types of soft tissue sarcoma (leiomyosarcoma and undifferentiated pleomorphic sarcoma). Twenty-five adults with advanced or in…
Phase: PHASE1, PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise for rare breast cancer
Disease control CompletedThis study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or o…
Phase: PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Real-World check: ovarian cancer drug niraparib under the microscope
Knowledge-focused CompletedThis study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No …
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Cancer Patients' COVID-19 immune response under the microscope
Knowledge-focused CompletedThis study followed 153 people with cancer who had or were suspected of having COVID-19. Researchers collected throat swabs and saliva samples over several weeks to see how well antibody and antigen tests work in this group. The goal was to learn more about the course of COVID-19…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:13 UTC